Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins

Vaccine

Volumn 18, Issue 7-8, 1999, Pages 665-674

  Lee, Na Gyong ^a   Jung, Sang Bo ^a   Ahn, Bo Young ^a   Kim, Young Gi ^a   Lee, Younha ^a   Jeon, Yeong Joong ^a   Park, Wan Je ^a  

^a CJ Corporation   (South Korea)

Author keywords

Human anti Oprs IgG; Large scale affinity purification; P. aeruginosa outer membrane proteins; Protective efficacy

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; GRAM NEGATIVE INFECTION; IMMUNOGENICITY; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED ICR; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS;

EID: 0005341847     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00273-X     Document Type: Article

References (40)

1. Spencer R.C. Predominant pathogens found in the European prevalence of infection in intensive care study. European Journal of Clinical Microbiology and Infectious Diseases. 15:1996;281-285.
2. Griffith S.J., Nathan R.K., Selander R.K., et al. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital. Journal of Infectious Diseases. 160:1989;1030-1036.
3. Korvick J.A., Marsh J.W., StarzI T.E., Yu V.L. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery. 109:1991;62-68.
4. McManus A.T., Mason A.D. Jr, McManus W.F., Pruitt B.A. Jr. Twenty-five year review of Pseudonionas aeruginosa bacteremia in a burn center. European Journal of Clinical Microbiology. 4:1985;219-223.
5. Pruitt B.A. Jr, Colonel M.C., McManus A.T. Opportunistic infections in severely burned patients. American Journal of Medicine. 30:1984;146-154.
6. Velasco E., Thuler L.C., Martins C.A., et al. Nosocomial infections in an oncology intensive care unit. American Journal of Infection Control. 25:1997;458-462.
7. Høiby N., Schiotz O. Immune complex mediated tissue damage in the lungs of CF patients with chronic Pseudomonas aeruginosa infection. Warwick W. 1000 years of cystic fibrosis. 1981;147-157 University of Minnesota Press, Minneapolis.
8. Fernandes P.M., Lundblad J.L. Preparation of a stable intravenous gamma-globulin: process design and scale-up. Vox Sanguinis. 39:1980;101-112.
9. Masuho Y., Tomibe K., Matsuzawa K., Ohtsu A. Development of an intravenous γ-globulin with Fe activities. I. Preparation and characterization of S-sulfonated human γ-globulin. Vox Sanguinis. 32:1977;175-181.
10. Schroeder D.D., Tankersley D.L., Lundblad J.L. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction. Vox Sanguinis. 40:1981;373-382.
11. Schroeder D.D., Tankersley D.L., Lundblad J.L. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. II. Functional characterization. Vox Sanguinis. 40:1981;383-394.
12. Cryz S.J. Jr, Fürer E., Sadoff J.C., et al. Production and characterization of human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. Journal of Infectious Disease. 163:1991;1055-1061.
13. Donta S.T., Peduzzi P., Cross A.S., et al. Immunoprophylactic against Klebsiella and Pseudomonas aeruginosa infections. Journal of Infectious Diseases. 174:1996;537-543.
14. Fisher M.W. A polyvalent human γ-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection. Journal of Infectious Diseases. 136:1977;S181-S185.
15. Jones C.E., Alexander J.W., Fisher M. Clinical evaluation of Pseudomonas hyperimmune globulin. Journal of Surgical Research. 14:1973;87-96.
16. Ogle J.D., Stace P., Alexander J.W. Extraction and purification of specific antibody against Pseudomonas aeruginosa by immune affinity chromatography. Journal of Laboratory and Clinical Medicine. 89:1977;433-438.
17. Gilleland H.E. Jr, Parker M.G., Matthews-Greer J.M., Berg R.D. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infection and Immunity. 44:1984;49-54.
18. Matthews-Greer J.M., Gilleland H.E. Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. Journal of Infectious Diseases. 155:1987;1282-1291.
19. von Specht B.-U., Lücking H.C., Blum B., et al. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine. 14:1996;1111-1117.
20. Stanislavsky E.S., Balayan S.S., Sergienko A.I., et al. Clinico-immunological trials of Pseudomonas aeruginosa vaccine. Vaccine. 9:1991;491-494.
21. Park W.J., Cho Y.J., Ahn D.H., et al. An outer membrane protein preparation as a vaccine against Pseudomonas aeruginosa infection. Journal of Microbiology and Biotechnology. 7:1997;144-150.
22. Jang I.-J., Kim I.-S., Park W.J., et al. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine. 17:1999;158-168.
23. Park W.J., Cho Y.J., Kim Y.G., et al. Active and passive protective effect of CFC-101 (Pseudomonas vaccine) in mice. Journal of Applied Pharmacology. 2:1994;326-330.
24. Inoue M., Mitsuhashi S., Fujimaki K., Noumi T. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy. 32:1988;827-833.
25. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin reagent. Journal of Biological Chemistry. 51:1951;89-96.
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
27. Lee N.-G., Jung S.B., Ahn B.-Y., et al. Preparation of a Vibrio vulnificus vaccine with immunogenicity and protective efficacy. Journal of Microbiology and Biotechnology. 7:1997;423-428.
28. Bhattacharjee A.K., Opal S.M., Taylor R., et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. Journal of Infectious Diseases. 173:1996;1157-1163.
29. Zollinger W.D., Mandrell R.E., Grifiss J.M., et al. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogen in man. Journal of Clinical Investigation. 63:1979;836-848.
30. Collins M.S., Ladehoff D.K., Mehton N.S., Noonan J.S. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. FEMS Immunology and Medical Microbiology. 64:1990;263-268.
31. Reed L.J., Muench J. A simple method of estimating fifty percent endpoint. American Journal Hygiene. 27:1938;493-497.
32. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of National Cancer Institute. 22:1959;719-748.
33. Akkoyunlu M., Janson H., Ruan M., Forsgren A. Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae. Infection and Immunity. 64:1996;4586-4592.
34. Lee N.-G., Ahn BY, Jung SB, et al. Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa. FEMS Immunology and Medical Microbiology, in press.
35. Pennington J.E., Small G.J., Lostrom M.E., Pier G.B. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infection and Immunity. 54:1986;239-244.
36. Sawada S., Suzuki M., Kawamura T., et al. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharide and outer membrane proteins. Journal of Infectious Diseases. 150:1984;570-576.
37. LoBuglio A.F., Wheeler R.H., Trang J., et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proceedings of National Academy of Sciences USA. 86:1989;4220-4224.
38. Reilly R.M., Sandhu J., Alvarez-Diez T.M., et al. Problems of delivery of monoclonal antibodies: pharmaceutical and pharmacokinetic solutions. Clinical Pharmacokinetics. 28:1995;126-142.
39. Collins M.S., Tsay G.C., Hector R.F., Roby R.E., Dorsey J.H. Therapy of experimental Pseudomonas burn wound sepsis with ciprofloxacin and Pseudomonas immune globulin. Antibiotic Chemotherapy. 39:1987;222-232.
40. Holder I.A., Neely A.N. Pseudomonas hyperimmune globulin: antibiotic treatment of experimental Pseudomonas sepsis in burned mice. Pseudomonas aeruginosa infection, Antibiotic Chemotherapy. 42:1989;109-123 Karger, Basel.